MB-101 received orphan drug designation for treating recurrent diffuse astrocytomas and glioblastoma, supporting rare disease treatments affecting fewer than 200,000 people in the U.S. Combining ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results